BRAF and thyroid cancer: Considering that the reactivation of MAPK/ERK pathway is a major cause of the resistance to BRAF kinase inhibitors such as PLX4032 [16], we next determined the impact of DSF/Cu on the response of BRAF-mutated thyroid cancer cells to PLX4032.